Skip to content
  • Sylentis
  • Blog
  • English English
    • English English
    • Español Español
  • Sylentis
  • Blog
  • English English
    • English English
    • Español Español
Syoligo, a Sylentis projectSyoligo, a Sylentis project
  • About IPCEI
  • Syoligo Project
  • R&D
  • FID
  • Events

Blog

Digital twin technology in bioprocessing: simulation and optimisation of pharmaceutical production
03
Jun
Optimisation of processes in the synthesis of oligonucleotides
28
Apr
World Book Day: three essential reads for gaining a deeper understanding of RNA and therapeutic oligonucleotides
23
Apr
The SYOLIGO project at major international oligonucleotide and RNA forums
24
Feb
Sylentis, a PharmaMar Group company, obtains Good Manufacturing Practice certification from the European Medicines Agency for its new industrial plant
02
Feb
Sylentis, compañía del Grupo PharmaMar, obtiene la certificación de Normas de Correcta Fabricación de la Agencia Europea de Medicamentos para su nueva planta industrial
21
Jan
2025: a decisive year for SYOLIGO on its third anniversary
14
Jan
siRNAs: advances, challenges and opportunities for European biotechnology
22
Dec
IPCEI Health MED4CURE: the project Syoligo by Sylentis, example of biomedical innovation with an impact on health and employment
16
Dec
Towards personalized RNA medicine in cardiovascular diseases
04
Nov
Sylentis strengthens its role as a leader in RNA biotechnology and oligonucleotide manufacturing
27
Oct
Sylentis strengthens its position in RNA biotechnology and consolidates its position as a pioneering CDMO in therapeutic oligonucleotides
15
Oct
Analytical methods in the manufacture of therapeutic oligonucleotides: ensuring quality and sustainability
13
Oct
Sylentis drives the debate on innovation and sustainability at Farmaforum 2025 by presenting the innovations of the SYOLIGO (IPCEI) project
24
Sep
The strategic role of CDMOs in the development of oligonucleotide-based therapies
08
Sep
Circular RNA: broadening horizons in RNA-based therapies
29
Aug
The Ministry of Science, Innovation and Universities grants 127 million euros to Spanish companies to promote research in the field of health and pharmaceutical production.
10
Jul
How is the first dose determined in humans for oligonucleotide therapies?
03
Jul
AI-Assisted Drug Design: Realities, Challenges and Future Prospects
16
Jun
Antisense oligos for the treatment of eye diseases
02
Jun
21.1 million euro grant awarded to SYOLIGO project by CDTI under the Recovery, Transformation and Resilience Plan
09
May
Sylentis, a PharmaMar Group company, will receive €21.1 million from the NextGenerationEU fund for research into rare diseases and the construction of a manufacturing plant
27
Mar
Sylentis participates in the First General Assembly and Annual Conference of IPCEI Med4Cure in Paris
18
Feb
Commission approves up to EUR 1 billion in state aid from seven Member States for the fourth major project of common European interest in the health sector
28
May

Pioneer in the development of drugs based on RNA interference (RNAi) technology. Develops new drugs using artificial intelligence with the goal of providing new medicines that improve the quality of life of patients.

Visit the sylentis website

SYOLIGO is an R&D and First Industrial Deployment project carried out by Sylentis for the development and sustainable manufacturing of RNA-based therapies for rare diseases in Spain and Europe.

About IPCEI
SYOLIGO Project
I+D
FID
Events
Blog

Funded by CDTI

legal notice privacy policy cookies policy
Copyright 2026 © SYLENTIS, S.A.
  • About IPCEI
  • Syoligo Project
  • R&D
  • FID
  • Events
Gestionar consentimiento
Para ofrecer las mejores experiencias, utilizamos tecnologías como las cookies para almacenar y/o acceder a la información del dispositivo. El consentimiento de estas tecnologías nos permitirá procesar datos como el comportamiento de navegación o las identificaciones únicas en este sitio. No consentir o retirar el consentimiento, puede afectar negativamente a ciertas características y funciones.
Funcional Always active
El almacenamiento o acceso técnico es estrictamente necesario para el propósito legítimo de permitir el uso de un servicio específico explícitamente solicitado por el abonado o usuario, o con el único propósito de llevar a cabo la transmisión de una comunicación a través de una red de comunicaciones electrónicas.
Preferencias
El almacenamiento o acceso técnico es necesario para la finalidad legítima de almacenar preferencias no solicitadas por el abonado o usuario.
Estadísticas
El almacenamiento o acceso técnico que es utilizado exclusivamente con fines estadísticos. El almacenamiento o acceso técnico que se utiliza exclusivamente con fines estadísticos anónimos. Sin un requerimiento, el cumplimiento voluntario por parte de tu proveedor de servicios de Internet, o los registros adicionales de un tercero, la información almacenada o recuperada sólo para este propósito no se puede utilizar para identificarte.
Marketing
El almacenamiento o acceso técnico es necesario para crear perfiles de usuario para enviar publicidad, o para rastrear al usuario en una web o en varias web con fines de marketing similares.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
Ver preferencias
{title} {title} {title}
  • English
  • Español (Spanish)